Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL
MetadataShow full item record
Key Points Higher ibrutinib DI is associated with improved PFS, independent of del17p or TP53 mutation. Ibrutinib hold for >1 week, often needed to manage adverse events, is associated with increased PFS events.
License start date
Blood, 2017, 129 (19), pp. 2612 - 2615
American Society of Hematology